MedTrace Logo

Long-Term Safety Of DVS-233 SR In Patients With Major Depressive Disorder

NCT01309542 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 1403

Last updated 2011-04-26

No results posted yet for this study

Summary

The study evaluated the long-term safety of Desvenlafaxine Succinate (DVS) Slow Release (SR) during open-label treatment in adult outpatients who had a primary diagnosis of major depressive disorder (MDD). The study also evaluated the long-term response of subjects receiving DVS SR for clinical global evaluation, functionality, general well-being, pain, and absence of depressive symptoms (remission).

Conditions

Interventions

DRUG

Desvenlafaxine Succinate

Tablet were taken at a daily dose of 200 to 400 mg/day for a duration up to 10 months

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-08-31
Primary Completion
2006-03-31
Completion
2006-03-31

Countries

  • United States
  • Estonia
  • Finland
  • France
  • Germany
  • Latvia
  • Lithuania
  • Poland
  • Serbia and Montenegro
  • Slovakia
  • South Africa

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01309542 on ClinicalTrials.gov